Neuvae Biotech

I researched antimicrobial resistance, the proposed role of phage therapy, and the immune-response component of the concept. As we built the deck, I separated findings we could cite from assumptions that belonged to our proposal and reduced the mechanism to the pieces the audience needed before we discussed the product idea.

We treated efficacy, delivery, safety, and regulatory approval as open questions. The pitch described the scientific rationale for Neuvae and the validation work that would have to follow, without presenting the concept as an experimentally proven treatment.

We organized the pitch around the antimicrobial-resistance problem, the proposed mechanism, and the experiments that would be needed next. I worked on the diagrams and writing together, using the diagrams for the biological mechanism and keeping the spoken explanation focused on what the concept was trying to change.

We reused the same research in a pitch deck, one-page summary, video, and article. The one pager carried the main claim and supporting evidence, while the longer formats included more of the mechanism and the unanswered development questions.

I wrote and delivered parts of the final pitch to a non-specialist audience, and the presentation received a TEDx award for best presentation. We kept the scientific explanation focused on antimicrobial resistance, phage therapy, and the proposed immune-response mechanism, then stated where the concept still depended on experimental validation.

Because Neuvae remained a research and venture proposal, we ended the presentation with the efficacy, delivery, safety, and regulatory questions that would have to be answered before the idea could move beyond that stage.